NO20084716L - Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases - Google Patents

Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases

Info

Publication number
NO20084716L
NO20084716L NO20084716A NO20084716A NO20084716L NO 20084716 L NO20084716 L NO 20084716L NO 20084716 A NO20084716 A NO 20084716A NO 20084716 A NO20084716 A NO 20084716A NO 20084716 L NO20084716 L NO 20084716L
Authority
NO
Norway
Prior art keywords
antisense oligonucleotides
inflammatory diseases
treating inflammatory
oligonucleotides against
inflammatory
Prior art date
Application number
NO20084716A
Other languages
English (en)
Norwegian (no)
Inventor
Eli Hazum
Lior Carmon
Original Assignee
Ester Neurosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ester Neurosciences Ltd filed Critical Ester Neurosciences Ltd
Publication of NO20084716L publication Critical patent/NO20084716L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01007—Acetylcholinesterase (3.1.1.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20084716A 2006-04-10 2008-11-07 Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases NO20084716L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79054606P 2006-04-10 2006-04-10
PCT/IL2007/000413 WO2007116395A2 (en) 2006-04-10 2007-03-29 Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases

Publications (1)

Publication Number Publication Date
NO20084716L true NO20084716L (no) 2009-01-02

Family

ID=38581474

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084716A NO20084716L (no) 2006-04-10 2008-11-07 Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases

Country Status (8)

Country Link
US (2) US20090275634A1 (de)
EP (1) EP2007399A2 (de)
JP (1) JP2009533421A (de)
AU (1) AU2007237059B2 (de)
CA (1) CA2648980A1 (de)
NO (1) NO20084716L (de)
NZ (1) NZ596382A (de)
WO (1) WO2007116395A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158600A (en) * 2003-10-26 2015-07-30 Hermona Soreq Dioxysoligonucleotide Antisense Against Acetylcholinesterase as an Anti-Inflammatory Agent
US20100329993A1 (en) 2007-06-29 2010-12-30 Hiroyuki Yoneyama Method of fixing and expressing physiologically active substance
WO2010018583A1 (en) * 2008-08-14 2010-02-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders
US10172916B2 (en) 2013-11-15 2019-01-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
US20160298114A1 (en) * 2015-03-18 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Haplotype Based Generalizable Allele Specific Silencing for Therapy of Cardiovascular Disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143379A (en) * 2001-05-24 2013-11-28 Yissum Res Dev Co Oligonucleotide against human ache isoform r and its uses
IL158600A (en) * 2003-10-26 2015-07-30 Hermona Soreq Dioxysoligonucleotide Antisense Against Acetylcholinesterase as an Anti-Inflammatory Agent
EP1791954A1 (de) * 2004-09-07 2007-06-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Agenten, zusammensetzungen und verfahren zur behandlung von krankheitsbildern, bei denen die regulation eines schmerzassoziierten biologischen wegs vorteilhaft ist
WO2006129164A1 (en) * 2005-05-31 2006-12-07 Pfizer Japan Inc. Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists

Also Published As

Publication number Publication date
WO2007116395A3 (en) 2007-12-27
US20090275634A1 (en) 2009-11-05
AU2007237059A1 (en) 2007-10-18
WO2007116395A2 (en) 2007-10-18
CA2648980A1 (en) 2007-10-18
AU2007237059B2 (en) 2013-01-24
US20120196920A1 (en) 2012-08-02
JP2009533421A (ja) 2009-09-17
NZ596382A (en) 2013-04-26
EP2007399A2 (de) 2008-12-31

Similar Documents

Publication Publication Date Title
MX2009006310A (es) Composiciones y metodos para tratar trastornos musculares y cardiovasculares.
MX2013009191A (es) Oligonucleotidos antisentido.
WO2010056982A3 (en) Compositions and methods for identifying autism spectrum disorders
WO2009045356A8 (en) Microrna compositions in the treatment of vegf-mediated disorders
WO2007091269A3 (en) NOVEL TANDEM siRNAS
WO2010129746A3 (en) Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
EP2963116A3 (de) Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt 1
MX358603B (es) Tratamiento de enfermedades relacionadas con un gen supresor de tumor mediante inhibicion del transcrito antisentido natural para el gen.
MX385869B (es) Agentes de iarn modificados.
WO2010138806A8 (en) Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
MX2011002966A (es) Formas de dosificacion farmaceutica que comprenden poli (e-caprolactona).
WO2008104978A3 (en) Novel sirna structures
WO2011084455A3 (en) Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
WO2009105260A3 (en) Ultra-small rnas as toll-like receptor-3 antagonists
WO2007022506A3 (en) Methods and compositions for treating neurological disease
MA31767B1 (fr) Composes organiques et leurs utilisations
WO2010151671A3 (en) Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
EP2957636A3 (de) Behandlung von sirtuin (sirt)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein sirtuin (sirt)
EP2633052A4 (de) Behandlung ifrd1-vermittelter erkrankungen durch hemmung des natürlichen antisense-transkripts gegen ifrd1
EA201200977A1 (ru) Лечение синдрома ли и ли-подобного синдрома токотриенолхинонами
WO2006083533A3 (en) Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
WO2010148065A3 (en) Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
NO20084712L (no) Nye farmasoytiske forbindelser
NO20084488L (no) Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
WO2008141308A3 (en) Gene expression and pain

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application